Salesforce Named as Quiet AI Play, but DeepValue Report Stresses Wait-Proof Metrics Needed

What happened

A MarketWatch article highlights Salesforce as one of five S&P 500 stocks quietly investing heavily in AI, suggesting investor interest beyond the Magnificent Seven. However, the latest DeepValue master report reiterates a "WAIT" rating on Salesforce, with a base case fair value of $170, reflecting scepticism that AI monetization has yet to translate into visible organic growth. The report's core concern remains that current remaining performance obligation (cRPO) growth must sustain above 14% and organic subscription revenue re-accelerate in the second half of fiscal 2027 to validate the AI bull case. While the news article adds to the broader AI narrative, it does not provide incremental evidence that Salesforce's Agentforce and Data 360 offerings are converting pilots into durable, higher-ACV renewals. Without near-term proof of cRPO stability or accelerating organic subscription growth, the stock's current 18.8x P/E offers limited margin of safety relative to the bear case of $145.

Implication

The MarketWatch piece reinforces that Salesforce is seen as a credible AI platform by some investors, but it does not address the revenue quality issues identified in the DeepValue report. The critical metric to watch remains cRPO growth, which must stay near the 14% guided level to support management's claim of organic acceleration in the second half of the year. If cRPO falls below 12%, the bear scenario of $145 becomes more likely, as it would signal seat compression or weaker renewal trends. Conversely, sustained cRPO above 14% and evidence of production-level Agentforce deployments could push the stock toward the $195 bull case. Until these data points emerge, the risk/reward is balanced at the current $163 price, and the "WAIT" rating remains appropriate.

Thesis delta

The article adds a mild positive sentiment tailwind by positioning Salesforce as a 'quiet' AI winner, but it does not change the fundamental thesis that proof of durable AI monetization is still pending. The key checkpoint remains Q2 FY27 earnings: cRPO must hold at ~14% and organic subscription growth must show reacceleration for the stock to break above $170. Without that confirmation, the 'show me' market sentiment will likely persist.